DAC
DAC_for_study_SEQCAP_Susceptibility_genes_for_the_development_of_SLE_during_treatment_of_IBD
| Dac ID | Contact Person | Access Information | |
|---|---|---|---|
| EGAC00001000111 | Carl Anderson | ca3 [at] sanger [dot] ac [dot] uk | No additional information is available |
This DAC controls 1 dataset:
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001000670 | A potential and very serious side effect of treating IBD with antiTNFa therapies (the currentgold standard) is the development of systemic lupus erythematosis (SLE). This side effect israre and unpredictable. Out of several thousand cases having received treatment, theUniversity of Calgary have accumulated 12 individuals with full phenotyping and novelserological antibody discovery panel data. We propose to exome sequence these samples inan effort to identify rare highly-penetrant variants that could be underlying this severephenotype. | Illumina HiSeq 2000 | 15 |
